Frederick, Maryland, September 9, 2021: BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform. BFI-751 is being developed by BioFactura Australia Pty Ltd, a subsidiary of BioFactura, as a biosimilar … Continue reading
Frederick, Maryland, May 25, 2021: BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first … Continue reading
Frederick, Maryland, February 19, 2021: BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at … Continue reading
Frederick, Maryland, September 24, 2020: BioFactura, Inc. was issued a new patent in the U.S. and also granted patent coverage in the EU for novel technologies that improve the productivity of its proprietary StableFastTM Biomanufacturing Platform. The new Multiplex Selection components of the platform allow for concurrent selection strategies to be applied during stable cell … Continue reading
Frederick, Maryland, July 27, 2020: BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based … Continue reading
Frederick, Maryland, September 26, 2019: BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox. This product has the potential to fulfill an … Continue reading
From U.S. Department of Health and Human Services By DHHS 26SEP2019 The U.S. Department of Health and Human Services will sponsor development of a novel therapeutic to treat smallpox infections. The variola virus, which causes smallpox was eradicated but remains a potential health security threat… Read Full Artic… Continue reading
Frederick, Maryland, April 29, 2019: The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. “With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as … Continue reading
From ClinicalTrialsArena.com By Elizabeth Williams 15AUG2018 CTA’s Elizabeth Williams catches up with Jeffrey Hausfeld, CMO, BioFactura, on the complexities of carrying out early phase studies. <Read Full Article>… Continue reading
Eric M. Mucker, Suzanne E. Wollen-Roberts, Adrienne Kimmel, Josh Shamblin, Darryl Sampey and Jay W. Hooper. PLOS Neglected Tropical Diseases. June 2018. Concerns regarding outbreaks of human monkeypox or the potential reintroduction of smallpox into an immunological naïve population have prompted the development of animal models and countermeasures. Here we present a marmoset model of monkeypox and smallpox disease utilizing a … Continue reading